Objective: Primary objective was to identify clinical factors and outcomes associated with leukocytosis in very low birth weight (VLBW) neonates. Secondary objective was to compare outcomes between infants with earlyonset (p72 h of age) and late-onset leukocytosis (>72 h).
Introduction
Discovery of leukocytosis in very low birth weight (VLBW) neonates, even among apparently healthy neonates, causes considerable angst among the clinical team and in most cases prompts a series of investigations and/or treatments. The terms leukocytosis or leukemoid reaction have been used to describe an abnormally elevated white blood cell (WBC) count. Hill and Duncan 1 used a threshold of WBC count >50 000 to define leukocytosis, whereas Zanardo et al.
2 used a cutoff of 40 000. Others used absolute neutrophil count values for defining pathology, for example, a count of >10 standard deviations above the mean for a given gestational age or an absolute neutrophil count of >30 000 during the first week after birth for diagnosing neutrophilia. [3] [4] [5] [6] Hsiao and Omar 7 used a cutoff point of absolute neutrophil count of >15 000 on the first day after birth and >10 000 after the first day. On the basis of these varied definitions, the incidence of leukocytosis in VLBW neonates is reported to vary between 1.3 and 17%. 3, [7] [8] [9] Varied etiologies (infection, inflammation, drugs, stress) at different time points (antenatal or postnatal) may contribute to altered WBC count in neonates. 5, 6, 10 Acute infection, which could lead to rapid clinical deterioration and serious complications, is one potentially treatable condition among these etiologies. Antenatal steroid treatment has been suggested as a possible cause of leukocytosis in preterm infants in some studies; [11] [12] [13] however, other studies have refuted this association. 3, 7, 14, 15 Leukocytosis is considered a reaction to or reflection of inflammatory processes under most circumstances; however, this needs verification in the neonatal population. 7, 16 An association between fetal inflammatory response syndrome and neonatal morbidities, especially chronic lung disease has been reported in small case series and case-control studies. 2, 7, 13 However, its association with other neonatal morbidities is not known.
Leukocytosis in VLBW infants presents a clinical dilemma. Early antibiotic treatment may prevent clinical deterioration if the cause for leukocytosis is sepsis, but uncontrolled antibiotic use could lead to increased bacterial resistance and predisposes infants to fungal infections. 17, 18 Our primary objective was to identify clinical factors associated with leukocytosis and to compare neonatal morbidity and mortality among VLBW infants with or without leukocytosis.
Secondary objective was to compare neonatal mortality and morbidity among infants with early-onset leukocytosis (p72 h of age) vs late-onset leukocytosis (>72 h of age).
Methods

Population
A matched cohort study of VLBW infants born at p30 weeks gestational age and admitted to two tertiary neonatal intensive care units (NICUs) between January 2002 and December 2004 was carried out. The study was approved by the institutional review boards of both hospitals.
Inclusion criteria
Cases were identified from the laboratory databases of both hospitals when at least one result of complete blood count revealed WBC count of X40 000. Each case infant was matched with a control infant without leukocytosis (WBC counts <35 000) who was born within 3 months of the index case in the same hospital and was born at a similar gestational age ( ± 1 week).
Exclusion criteria
We excluded babies diagnosed with trisomy 21, as they are at an increased risk of developing a leukemoid reaction and leukemia during the infantile period. Infants who died or who were transferred to another hospital on the first day after birth were also excluded from the study.
Data collection and definitions
The primary comparison was between the group of infants with leukocytosis and the cohort of matched infants without leukocytosis. We further distinguished between and compared cases who were diagnosed with early leukocytosis (EL) p72 h of birth and those with late leukocytosis (LL) that is, when leukocytosis was diagnosed after 72 h of birth (a cutoff point equivalent to the one used for defining early and late-onset sepsis in neonates). The LL cohort was matched for comparable postnatal age at the time of diagnosis. We analyzed this cutoff point hypothesizing that antenatal factors may be important in EL, whereas postnatal factors play a major influence in LL. Antenatal factors included conditions considered as risk factors for infection or inflammation such as group B streptococcal carrier status, cervical cerclage placement, chorioamnionitis and treatment with steroids. Chorioamnionitis was diagnosed by a positive amniotic fluid culture or by two or more of the following: prolonged rupture of membranes >18 h, maternal fever, fetal tachycardia or foulsmelling liquor. Placental pathology was available in the minority of cases. Neonatal data consisted of age at the diagnosis of leukocytosis, time to peak and resolution, results of culture status and subsequent antibiotic treatment. Neonatal sepsis was diagnosed if a pathogenic organism was isolated from one of the usually sterile sites such as blood, urine or cerebrospinal fluid (CSF). Positive endotracheal cultures were considered as suspected sepsis if associated with radiological changes and/or respiratory deterioration.
Data on outcomes were retrieved from infants' charts. These included common neonatal morbidities and mortality. Necrotizing enterocolitis (NEC) was defined as Xstage 2 according to modified Bell's criteria. 19 Chronic lung disease was diagnosed as oxygen requirement at 36 weeks postmenstrual age. 20 Retinopathy of prematurity was classified according to international classification. 21 Cranial ultrasound findings were classified according to Papile's classification. 22 Thrombocytopenia was defined as platelet count <150 Â 10 9 per liter.
Statistical analysis
Statistical analyses were performed using SPSS (version 15.0, Chicago, IL, USA). Continuous variables were compared using Student's t-test and Mann-Whitney U-test as appropriate. Categorical variables were compared using Fisher's exact test or w 2 -test as appropriate. A P-value of <0.05 was considered significant. Demographic variables and outcomes characteristics were compared between infants with leukocytosis and without leukocytosis and between infants who had EL and LL.
Results
A total of 1572 VLBW infants of <30 weeks gestation were admitted to both centers during the study period. Of these, 96 eligible patients had leukocytosis yielding an incidence rate of 6.1%. We identified 94 eligible controls during this period. No eligible matched control could be found for two infants (of 24 and 27 weeks gestational ages). There were no differences in baseline demographic characteristics (gestational age, birth weight, sex, Apgar scores, intrauterine growth restriction or surfactant administration) between infants with and without leukocytosis. There were also no differences in the incidences of predisposing factors such as chorioamnionitis, cervical cerclage, administration of corticosteroids or group B streptococcal carrier status (Table 1 ). All infants with leukocytosis were investigated for infection. Twentytwo (22%) infants had culture-proven infection. Four infants had fungal infection. No differences in mortality, neonatal morbidities or length of stay were identified between infants with and without leukocytosis ( Table 2) .
Early-onset leukocytosis was detected in 48% (n ¼ 46) of the cases and late-onset leukocytosis in the remaining 52% (n ¼ 50) of cases. A higher number of infants were exposed to antenatal steroid in the EL group; however, there were no significant differences in the demographic or clinical features between these two groups ( Table 1 ). The incidences of culture-proven sepsis, NEC and associated thrombocytopenia were higher in LL group compared to EL group. There were no differences in other morbidities, mortality or length of hospitalization between EL and LL group ( Table 2 ). The temporal pattern of leukocytosis and organisms responsible for infections for both EL and LL group are reported in Table 3 .
Discussion
In this large series of infants with leukocytosis, the incidence of leukocytosis was 6.1%. No differences in the predisposing factors or neonatal outcomes were identified between VLBW infants with and without leukocytosis. Approximately a quarter of patients with leukocytosis were diagnosed with culture-proven infections. EL was associated with exposure to antenatal steroids, whereas LL was associated with higher incidences of infection and NEC. Together, these findings suggest that different etiologies lead to significant leukocytosis at different time points in the clinical courses of VLBW infants.
The incidence of leukocytosis in this study was within the reported range of 1.3 to 17% published in the literature. Different etiologies are suggested as causes for elevated WBC count in preterm infants. 7, 8 We identified an association between antenatal steroids exposure and EL. Steroids are known to cause neutrophilia by accelerating release of leukocytes from bone marrow and reducing their egress from the blood into the tissue. 23 However, Calhoun et al. 3 in a report of bone marrow samples from four VLBW infants born at <30 weeks gestational age identified an increased production of neutrophils, suggesting a kinetic mechanism rather than a corticosteroid-induced release of neutrophils from the bone marrow as the main cause of leukocytosis. Histologic chorioamnionitis was also suggested to Approximately a quarter of infants in our series had cultureproven sepsis. Nakamura et al.
9 studied 14 VLBW infants with EL; all of whom had negative blood cultures. Hsiao and Omar 7 observed a link between leukemoid reaction and clinical sepsis, but commented on a low yield of the culture method. We included urine, CSF and catheter fluid in considering culture-proven sepsis in accordance to the most commonly used definition. It is not an uncommon practice to initiate empirical antifungal therapy for an infant with leukocytosis. Fungal infection was identified in only four cases, although antifungal therapy was initiated for 26 infants in our series. The incidence of infection was significantly higher with LL compared to EL. Causative organisms were not different than the usual organism pattern identified in VLBW infants in NICU. 24, 25 An association between NEC and LL has not been reported previously. These infants also had thrombocytopenia, a common laboratory finding at times of infection or NEC. 26 The difference in NEC rates between EL and LL is attributable not only to a high rate in the late group but a low rate in the early group (lower than controls). Could EL indicate protection from the risk of NEC? Could the difference be simply an indicator of antenatal steroid administration? These important questions cannot be answered by the current study design.
We identified that other morbidities and mortality rates were similar between the groups. This is inconsistent with most other studies that have reported a longer hospitalization and a higher rate of bronchopulmonary dysplasia among infants with leukemoid reaction. 7, 9, 13, 16 Most studies have attributed the increased risk of lung morbidity to ureaplasma infection/colonization and to inflammation. 13, 16 In our series, seven infants in the EL group had ureaplasma in their endotracheal aspirates. This number is almost certainly an underestimate of the rate of ureaplasma colonization, as endotracheal aspirates were not routinely sent in all infants.
Previous studies of leukocytosis have either been small case reports or cohort studies identifying only a small number of infants with leukocytosis. [7] [8] [9] 12, 14, 15, 27 The strengths of our study include large number of cases from two large NICUs, selective population of VLBW infants, differentiation of population into EL and LL and near completeness of neonatal outcome data. The matched cohort design ensured comparability between groups for the most important baseline and clinical characteristics. However, limitations of our study include a retrospective design and varied management strategies once the diagnosis of leukocytosis was made, which may have influenced the course. Future prospective studies with use of complimentary inflammatory markers, consistent management plans, detailed exploration of the risk factors and long-term outcome are warranted; however, this may need a multicenter collaboration. Standardization of diagnosis and format for reporting laboratory results is also needed. Sepsis was suspected when isolation of pathogenic organism was confirmed from sites other than blood, urine or CSF.
Leukocytosis in VLBW infants I Morag et al
In conclusion, the incidence of leukocytosis in our population was 6.1%. The incidence of culture-proven sepsis among patients with leukocytosis was 22%. There were no differences in mortality or morbidities between patients with leukocytosis and those without leukocytosis. Late-onset leukocytosis was associated with sepsis and NEC, indicating that the postnatal age at the time of detection of leukocytosis should be considered when clinical decisions are made. Before any change in antibiotic treatment could be recommended, more data regarding the association of EL and sepsis should be collected, especially by analyzing placental pathology, endotracheal cultures and other inflammatory markers (C-reactive protein or CD 64). As suggested by others, we agree that the use of antifungal medication in infants with leukocytosis should be considered in view of the unit's baseline fungal infection rate and other known risk factors. 28, 29 Findings of this research indicate that future prospective studies of complimentary inflammatory markers, short-term neonatal and long-term neurodevelopmental outcomes are warranted.
